In that case, the percentage of patients with non-IPF-ILD who exhibited progression within 1 year was significantly higher in the CCL17 high group than in the CCL17 low group (50.00% vs. 4.55%; P = 0.0011) (Fig. 3E and F). The gene discussed is CCL17; the disease is interstitial lung disease.